Live Webinar: 9 February 2022, 4 pm CET
Organised by ECTS
Sponsored by Industry
Date & Time: 9 February 2022, 4 pm CET
Featuring Prof. Dr. José A. Riancho Chaired by Nuria Guanyabens & Cristiana Cipriani
Costs: Live & On-Demand webinar is free for ECTS members and non-members, but a registration is required.
- 5 min introduction
- 25 min meet-the-expert presentation
- 30 min Q&A and Case Discussion
- To raise awareness of the presentation of hereditary skeletal disorders in adults
- To understand the diagnostic work up of patients with low alkaline phosphatase
- To know the skeletal consequences of mild hypophosphatasia in adults
- To understand the benefits and drawbacks of therapy in adult patients with hypophosphatasia
“The ECTS Rare Bone Diseases Webinar – Managing adults with low alkaline phosphatase, Brussels, Belgium, 09/02/2022-09/02/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”
“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”
Featuring Prof. Dr. José A. Riancho
José A. Riancho is Professor of Medicine at the University of Cantabria, as well as Chief of Section of Internal Medicine at the University Hospital M. Valdecilla, both in Santander, Spain. He has extensive clinical experience in the management of patients with osteoporosis and other metabolic bone disorders. His research is focused on the genomics and epigenomics of osteoporosis and other skeletal disorders. He has published more than 200 papers in international peer-reviewed journals, including several studies about the clinical and genetic characteristics of adult patients with hypophosphatasia. He is a member of the the Spanish Society for Research on Osteoporosis and Mineral Metabolism (SEIOMM), The European Society of Calcified Tissues, and the American Society for Bone and Mineral Research. He also participates in several international consortia investigating the genetic basis of skeletal disorders.
Moderated by Dr Thomas Funck-Brentano
Breast cancer cells frequently disseminate to the bone marrow, where they may either enter a dormant state or colonize the bone and induce osteolysis. The mechanisms that regulate tumor cell entry and exit from dormancy in the bone are not well understood, but several factors have been identified. Previous work from our group found that leukemia inhibitory factor receptor (LIFR) promotes tumor dormancy when expressed on bone-disseminated tumor cells and that loss of LIFR enables otherwise dormant tumor cells to colonize the bone. Our lab has therefore examined how LIFR expression is regulated in breast cancer cells, with the hope that understanding its regulation might provide novel avenues to therapeutically target dormant disseminated tumor cells. Through these efforts we have found that LIFR is epigenetically regulated, and that histone deacetylase (HDAC) inhibitors, which are FDA-approved for several blood cancers, stimulate LIFR expression on breast cancer cells from all subtypes. This finding presents an interesting therapeutic opportunity to explore whether HDAC inhibitors may be used to promote a chronic state of tumor dormancy and prevent recurrence in bone. Our findings suggest that this may be feasible, but that the effects of histone deacetylase inhibitors on bone remodeling profoundly impact tumor colonization and must be combined with appropriate anti-resorptive therapies.